Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

References

• Dimpopoulous MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the fourth International Workshop on Waldenstrom's Macroglobulinaemia. J Clin Oncol 2009; 27:120–126.
   PubMed Web of Science ®Google Scholar
• Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanism features compared with other alkylating agents. Clin Cancer Res 2008;14:309–317.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014;123: 2944–2952.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Puccini B, Cortelazzo S, et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients: a multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol 2012;91:1013–1022.
   PubMed Web of Science ®Google Scholar
• Buske C, Leblonde V, Dimopoulous M, et al. Waldenstrom's macroglobulinaemia: ESMO Clinical Practice for diagnosis, treatment and follow-up. Ann Oncol 2013;24:155–159.
   Web of Science ®Google Scholar
• Anderson KC, Alsina M, Bensinger W, et al. Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Cancer Netw 2012;10:1211–1219.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:133–135.
   PubMed Web of Science ®Google Scholar
• Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013;160:171–176.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). Available from: evs.nci.nih.gov
   Google Scholar
• Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disordes: IWWM-7 consensus. Blood 2014;124: 1404–1411.
   PubMed Web of Science ®Google Scholar
• Derenzini E, Zinzani PL, Cheson BD. Bendamustine:role and evidence in lymphoma therapy, an overview. Leuk Lymphoma 2014;55:1471–1478.
   PubMed Web of Science ®Google Scholar
• Ioakimidis L, Patterson C, Hunter Z, et al. Comparative outcomes following CP-R, CVP-R and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:62–66.
   PubMedGoogle Scholar
• Tedeschi A, Ricci F, Goldaniga MC, et al. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13:231–234.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113:3673–3678.
   PubMed Web of Science ®Google Scholar
• Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biological results of a phase II multi center study. J Clin Oncol 2010;28:2233–2238.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012;15:434–443.
   Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344–3349.
   PubMed Web of Science ®Google Scholar
• Treon SP, Emmaouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom's macroglobulinamia. Ann Oncol 2005;16: 132–138.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327–2333.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009;23:153–161.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Machmeyer G, et al. Bendamustine-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenstrom's macroglobulinemia: results from a prospective randomized multicentre study (Stil NHL 7-2008 – MAINTAIN; Clintrials.gov Identifier: NCT00877214). Blood 2012;120:(Suppl. 1): Abstract 2739.
   Google Scholar
• Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;10:250–255.
   Web of Science ®Google Scholar
• Peinert S, Tam CS, Prince HM, et al. Fludarabine based combinations are highly effective as first line or salvage treatment in patients with Waldenstrom macroglobulinemia. Leuk Lymphoma 2010;51:2188–2197.
   PubMed Web of Science ®Google Scholar
• Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoblastic lymphoma. J Clin Oncol 2013;20:301–317.
   Web of Science ®Google Scholar
• Varettoni M, Tedeschi A, Arcaini L, et al. Risk of second cancers in Waldenstrom's Macroglobulinemia. Ann Oncol 2012;23: 411–415.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:2227–2232.
   PubMed Web of Science ®Google Scholar
• Anastasia A, Pulsoni A, Re A, et al. Mobilization of hematopoietic stem cells by a bendamustine-containing regimen in Hodgkin's lymphoma. Blood 2012;120(Suppl. 1): Abstract 1914.
   Google Scholar